Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQC2731 in Chronic Rhinosinusitis With Nasal Polyps
NCT07107256Phase 3Active, not recruiting
- Sponsor
- Chia Tai Tianqing
- Start
- Sep 2025
- Primary completion
- Mar 2027
- Modality
- IgG Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing TQC2731 injection with Placebo of TQC2731 (2 arms). Primary endpoints: Nasal Polyp Score at Week 24 and Nasal Congestion Score at Week 24. Started Sep 2025; status: active, not recruiting.
02
Drugs
bosakitug
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT07107256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107256.